Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2026
Reporting Period: Event date January 7, 2026
Business Context: The registrant is a Delaware corporation listed on the Nasdaq Capital Market. It operates a wholly owned laboratory subsidiary, Precision Pathology Laboratory Services.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory event rather than financial performance data.
Material Changes
Accreditation Status: On January 7, 2026, the company announced that its subsidiary, Precision Pathology Laboratory Services, successfully maintained its accreditation from the College of American Pathologists (CAP) following an on-site inspection.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) confirming the successful maintenance of CAP accreditation.
Outlook and Risks: The filing text does not provide specific forward-looking guidance, risk factors, or details on contingencies beyond the successful accreditation event.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the inspection scope.
- Confirm the current accreditation status of Precision Pathology Laboratory Services on the College of American Pathologists website.
- Review subsequent filings for any financial impact related to the laboratory operations.